DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/bbt38x/breast_cancer)
has announced the addition of the “Breast
Cancer Therapeutics in Major Developed Markets to 2021 – Growth Driven
by Rapid Uptake of Premium Priced Biologics and Rising Incidence”
report to their offering.
Breast Cancer Therapeutics in Major Developed Markets to 2021 – Growth
Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence
Breast cancer, a malignant neoplasm, is the second most common cancer
and the most common cancer in women worldwide, accounting for 16% of all
female cancers, making the disease exceedingly prevalent. The number of
women diagnosed with breast cancer has increased over the past few
decades, but the number of deaths has declined due to earlier diagnosis
and better treatment options.
Breast cancer treatment has been revolutionized in the past four
decades, especially with increasing usage of targeted therapies. The
marketed products landscape comprises a wide range of treatment options,
including hormonal therapies, chemotherapies, combination therapies, and
targeted therapies. Nevertheless, significant unmet need remains for
products that can improve overall survival rate, time to disease
progression, and overall response.
The current breast cancer market contains novel products, including
Perjeta, a targeted therapy; Kadcyla, a human antibody-drug conjugate;
and Halaven, a novel chemotherapeutic agent.
– What are the competitive advantages of the existing novel drugs?
With over 700 active pipeline molecules, most of the investigational
drug candidates are being evaluated for the first-line or second-line
treatment of advanced-stage breast cancer, featuring new combination
therapies, targeted therapies, and promising immunotherapies, as well as
chemotherapy drug candidates.
– Which classes of novel drugs are most prominent within the pipeline?
– Is there strong potential for the pipeline to address unmet needs
within the breast cancer market?
Analysis of clinical trials since 2006 identified that the failure rates
of breast cancer molecules were highest in Phase II (41%), with the
overall attrition rate for breast cancer in development being 61%.
– How do failure rates vary by product stage of development, molecule
type, and mechanism of action?
– How do other factors, such as average trial duration and trial size
influence the costs and risks associated with product development?
Over the 2014-2021 forecast period, the breast cancer therapeutics
market in the eight major markets is expected to increase in value at a
CAGR of 7.3%, from $10.4 billion to over $17.2 billion.
– Which markets make the most significant contribution to the current
– What are the epidemiology trends in these markets?
– Will new market entrants lead to substantial changes in annual therapy
– How will different treatment usage patterns impact growth in the eight
Rising breast cancer incidence and new product approvals will lead to
significant market growth over the forecast period, despite generic
sales erosion resulting from patent expirations.
– Will patent expirations or emerging pipeline molecules threaten the
commercial success of existing drugs?
– Which patent expirations will have the most significant impact on the
Key Topics Covered:
1 Tables & Figures
3 Marketed Products
4 Pipeline Products
5 Promising Drug Candidates in Pipeline
6 Market Forecast to 2021
7 Drivers and Barriers for the Disease Market
8 Deals and Strategic Consolidations
- Array BioPharma
- Bristol-Myers Squibb
- CTI BioPharma
- Color Genomic
- Eli Lily
- Halozyme Therapeutics
- OBI Pharma
- Puma Biotechnology
- Roche Holding
- Sprint Bioscienc
- University of California Health
For more information visit http://www.researchandmarkets.com/research/bbt38x/breast_cancer
Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Fax (outside U.S.): +353-1-481-1716